IRWDHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Ironwood Pharmaceuticals, Inc. hold a median 12-month price target of $5.35 — +48.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Ironwood Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Volatility (45): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IRWD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +48.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Feb 2026 | Citizens | Maintains | Market Outperform | $8.00 → $10 |
| 5 Jan 2026 | Citizens | Upgrade | Market Outperform | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Apr 2025 | Jefferies | Downgrade | Hold | — |
| 15 Apr 2025 | Wells Fargo | Downgrade | Equal-Weight | — |
| 14 Apr 2025 | Leerink Partners | Maintains | Market Perform | — |
| 30 Jan 2025 | JMP Securities | Maintains | Market Outperform | — |
| 22 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 9 Sept 2024 | Leerink Partners | Initiates | Market Perform | — |
| 9 Aug 2024 | Craig-Hallum | Maintains | Buy | — |
| 9 Aug 2024 | Wells Fargo | Maintains | Overweight | — |
| 10 May 2024 | Craig-Hallum | Maintains | Buy | — |
| 1 Mar 2024 | Wells Fargo | Maintains | Overweight | — |
| 16 Feb 2024 | Piper Sandler | Maintains | Overweight | — |
| 17 Jan 2024 | Craig-Hallum | Initiates | Buy | — |
| 14 Dec 2023 | Wells Fargo | Initiates | Overweight | — |
| 28 Sept 2023 | JMP Securities | Initiates | Market Outperform | — |
| 23 May 2023 | Piper Sandler | Maintains | Overweight | — |
| 29 Aug 2022 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRWD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Ironwood Pharmaceuticals, Inc. returned +143.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 58% of US stocks
Cheaper than 96% of US stocks
Cheaper than 55% of US stocks
Higher than 79% of US stocks
Higher than 85% of US stocks
Higher than 99% of US stocks
Higher than 92% of US stocks
Higher than 37% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ironwood Pharmaceuticals, Inc. has a market value of $593.2M and an enterprise value of $939.0M.
Revenue in the twelve months to 30 June 2026: $389.3M. The latest quarter grew 32.6% year on year.
Net income over the same four quarters: $129.9M, a 33.4% net margin.
Diluted earnings per share, trailing twelve months: $0.77.
Free cash flow in the twelve months to 30 June 2026: $185.6M.
Trailing P/E: 4.7×; forward P/E: 2.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ironwood Pharmaceuticals, Inc. employs 100 people — $3.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ironwood Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Linzess demand remains strong, while a recent pediatric label expansion and pricing changes are positioned to support Ironwood's third-quarter 2026 growth.
Why it matters — Linzess demand and the label and pricing changes are relevant to investors tracking Ironwood's top-line growth.
Seeking Alpha rates Ironwood Pharmaceuticals Buy, arguing that its investment case depends on apraglutide and the STARS-2 trial rather than Linzess. The excerpt notes expected generic competition and Medicare price cuts affecting Linzess, while modeling apraglutide peak sales conservatively at $456 million.
Why it matters — IRWD watchers may focus on STARS-2 results and approval timing as key uncertainties amid pressure on Linzess cash flows.
A Zacks Investment Research article compares Precigen and Ironwood Pharmaceuticals, noting that Precigen's Papzimeos and Ironwood's Linzess are driving growth. The piece highlights how competition, pipeline progress, and reliance on a single product shape each company's outlook.
Why it matters — Ironwood watchers would care because the article examines how Linzess and single-product reliance and competitive pressures could affect the company's growth prospects relative to a peer.
Zacks Investment Research highlighted Ironwood Pharmaceuticals as a top-ranked momentum stock, referencing its Style Scores feature from the Zacks Premium research service as a tool for identifying strong stocks. The piece focuses on the company's momentum among investors.
Why it matters — A favorable momentum ranking from a widely followed research service brings added attention to IRWD, which could interest current and prospective shareholders tracking the stock's performance.
Zacks Investment Research highlighted Ironwood Pharmaceuticals (IRWD) alongside INDV, RLMD, LRMR and CRDL as small drug stocks that could offer significant upside as biotech sentiment improves, citing catalysts and differentiated pipelines as supporting factors.
Why it matters — A favorable analyst mention of IRWD's pipeline and catalysts may raise visibility and investor interest in the company's prospects amid a recovering biotech sector.
The 4 Wall Street analysts covering Ironwood Pharmaceuticals, Inc. have a median 12-month price target of $5.35, with estimates ranging from $3.7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Ironwood Pharmaceuticals, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ironwood Pharmaceuticals, Inc. 100 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Ironwood Pharmaceuticals, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +48.6% from the last close, and Ticker Nerd's factor model ranks Ironwood Pharmaceuticals, Inc. 100 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ironwood Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $10 over the next 12 months.
Ironwood Pharmaceuticals, Inc. returned +143.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ironwood Pharmaceuticals, Inc. Class A Common Stock represents ownership in Ironwood Pharmaceuticals, Inc., a biotechnology company focused on developing and commercializing therapies for gastrointestinal disorders and rare diseases.
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?". Linzess demand remains strong, while a recent pediatric label expansion and pricing changes are positioned to support Ironwood's third-quarter 2026 growth.
Ironwood Pharmaceuticals, Inc. Class A Common Stock represents ownership in Ironwood Pharmaceuticals, Inc., a biotechnology company focused on developing and commercializing therapies for gastrointestinal disorders and rare diseases. Its current business centers on human therapeutics, with an emphasis on medicines for conditions such as irritable bowel syndrome with constipation and chronic idiopathic constipation. The company’s commercial portfolio is anchored by LINZESS, a treatment used in gastrointestinal care, while its broader pipeline reflects ongoing work in GI-focused and other specialty medicine programs. Headquartered in Boston, Massachusetts, Ironwood serves patients, healthcare providers, and commercial partners through product development, marketing, and lifecycle management in the pharmaceutical sector. As a publicly traded healthcare company, it plays a role in the specialized drug market by addressing areas of significant unmet medical need.
CEO Mr. Thomas A. McCourt · 100 employees · United States · https://ironwoodpharma.com
